Ani Pharmaceuticals (ANIP) Share-based Compensation (2010 - 2026)

Ani Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $10.2 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.2 million, up 14.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.3 million (up 25.49% YoY), and the FY2025 annual result was $37.9 million, up 29.26% from the prior year.
• Share-based Compensation came in at $10.2 million for Q1 2026 at Ani Pharmaceuticals, up from $9.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q1 2026 to a low of $10000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $6.9 million (2024), against an average of $6.2 million.
• Across the five-year window, Share-based Compensation sank 99.32% in 2022 and surged 54340.0% in 2023, its largest moves.
• Ani Pharmaceuticals' Share-based Compensation stood at $3.7 million in 2022, then jumped by 50.41% to $5.6 million in 2023, then climbed by 25.62% to $7.1 million in 2024, then soared by 38.34% to $9.8 million in 2025, then increased by 4.33% to $10.2 million in 2026.
• The last three Share-based Compensation figures came in at $10.2 million (Q1 2026), $9.8 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.